Clinical Trial Update: An Investigation of rhTPO With Different Frequencies in the Management of ITP [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating different dosing frequencies of recombinant human thrombopoietin (rhTPO) for immune thrombocytopenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• rhTPO (recombinant human thrombopoietin)

Snippet

Sponsor: Shandong University | Conditions: Immune Thrombocytopenia | Phase 3 | Status: COMPLETED